AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34323448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency ablation (CRFA)
Number of subjects: 136
Study 34323448 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat CRFA
Number of subjects: 136
Study 32687836 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS to the left IFG/LipM1 and cathodal tDCS to the right hemisphere homologue
Number of subjects: 60
Study 32687836 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS over the left and anodal over the right
Number of subjects: 60
Study 32687836 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 60
Study 32687836 — intervention group
Group type: EXPERIMENTAL
Intervention: All stimulation groups (Anodal, Cathodal, Sham)
Number of subjects: 60
Study 36424914 — intervention group
Group type: EXPERIMENTAL
Intervention: iTClamp
Number of subjects: 20
Study 36424914 — intervention group
Group type: COMPARATOR
Intervention: Pressure dressing
Number of subjects: 20
Study 36424914 — intervention group
Group type: EXPERIMENTAL
Intervention: iTClamp and Pressure dressing
Number of subjects: 20
Study 34933545 — intervention group
Group type: EXPERIMENTAL
Intervention: New electromagnetic and vibrating device
Number of subjects: 0
Study 34933545 — intervention group
Group type: COMPARATOR
Intervention: Alpha-blocker agents
Number of subjects: 0
Study 34321096 — intervention group
Group type: EXPERIMENTAL
Intervention: Epratuzumab (monoclonal antibody targeting CD22)
Number of subjects: 0
Study 32385848 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Literacy (HL)
Number of subjects: 579
Study 35504550 — intervention group
Group type: COMPARATOR
Intervention: Topical antiviral therapy (TAT)
Number of subjects: 45
Study 35504550 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobial photodynamic therapy (aPDT)
Number of subjects: 45
Study 35504550 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antiviral therapy + adjunctive antimicrobial photodynamic therapy (TAT + aPDT)
Number of subjects: 45
Study 35288009 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml/kg carbohydrate (≤400 ml) 2 hours before surgery
Number of subjects: 86
Study 35288009 — intervention group
Group type: COMPARATOR
Intervention: Fasting for 6 hours and forbidden from drinking water for 4 hours before surgery
Number of subjects: 86
Study 34619044 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD (300 mg daily for 14 days)
Number of subjects: 105
Study 34619044 — intervention group
Group type: COMPARATOR
Intervention: Placebo (added to standard symptomatic care for 14 days)
Number of subjects: 105
Study 32574506 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOT-EMI (Hyperbaric Oxygen Therapy and Exercise and Mental Imagery)
Number of subjects: 27
Study 32574506 — intervention group
Group type: COMPARATOR
Intervention: EMI alone (Control)
Number of subjects: 27
Study 35379762 — intervention group
Group type: EXPERIMENTAL
Intervention: siponimod
Number of subjects: 1830
Study 35379762 — intervention group
Group type: EXPERIMENTAL
Intervention: fingolimod
Number of subjects: 1830
Study 35379762 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1830
Study 33662265 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 348
Study 33662265 — intervention group
Group type: COMPARATOR
Intervention: No SMS reminders
Number of subjects: 348
Study 32859658 — intervention group
Group type: COMPARATOR
Intervention: Healthcare use (HCU) at baseline
Number of subjects: 443
Study 35201404 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued CPAP
Number of subjects: 37
Study 35201404 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 37
Study 33431386 — intervention group
Group type: EXPERIMENTAL
Intervention: interactive e‐consent
Number of subjects: 734
Study 33431386 — intervention group
Group type: EXPERIMENTAL
Intervention: trust‐enhanced e‐consent
Number of subjects: 734
Study 33431386 — intervention group
Group type: COMPARATOR
Intervention: standard e‐consent
Number of subjects: 734
Study 34375409 — intervention group
Group type: EXPERIMENTAL
Intervention: Text Messaging Intervention (TMI) - 174 automated text messages plus a group smoking counseling session and provision of nicotine patches
Number of subjects: 77
Study 34375409 — intervention group
Group type: EXPERIMENTAL
Intervention: Text Messaging Intervention (TMI)
Number of subjects: 77
Study 34375409 — intervention group
Group type: COMPARATOR
Intervention: Control (Standard Care)
Number of subjects: 77
Study 34569204 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint application of Chinese herbal medicine (Rhizome Pinelliae Preparata, Ginger, Clove) for 6 hours before anesthesia induction, changed after 24 hours, lasting for 2 days.
Number of subjects: 168
Study 34569204 — intervention group
Group type: COMPARATOR
Intervention: Control group received placebo plasters (flour and excipients with 10% of experimental drug concentration) for 6 hours before anesthesia induction, changed after 24 hours, lasting for 2 days.
Number of subjects: 168
Study 32083686 — intervention group
Group type: COMPARATOR
Intervention: White male physician (control)
Number of subjects: 3592
Study 32083686 — intervention group
Group type: EXPERIMENTAL
Intervention: White female physician
Number of subjects: 3592
Study 32083686 — intervention group
Group type: EXPERIMENTAL
Intervention: Black female physician
Number of subjects: 3592
Study 32083686 — intervention group
Group type: EXPERIMENTAL
Intervention: Black male physician
Number of subjects: 3592
Study 35887701 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive vascular occlusion stimulus (RVOS) applied twice daily for 10 days (4 cycles of 5 min tourniquet inflation to 50 mmHg supra-systolic blood pressure, and 5 min complete deflation)
Number of subjects: 12
Study 35887701 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive vascular occlusion stimulus (RVOS)
Number of subjects: 12
Study 35887701 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 12
Study 34237973 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin-loaded calcium phosphate cement (CPC) after debridement
Number of subjects: 98
Study 34237973 — intervention group
Group type: COMPARATOR
Intervention: Irrigation and drainage device with irrigated antibiotics
Number of subjects: 98
Study 35565826 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of a lecithin‐based delivery form of Boswellia serrata (CASP) for 5 days
Number of subjects: 49
Study 35565826 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 49
Study 35565826 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of a lecithin‐based delivery form of Boswellia serrata (CASP)
Number of subjects: 49
Study 33559686 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided insertion of Ambu AuraGain™
Number of subjects: 72
Study 33559686 — intervention group
Group type: COMPARATOR
Intervention: Non-guided insertion of Ambu AuraGain™
Number of subjects: 72
Study 36169949 — intervention group
Group type: COMPARATOR
Intervention: Single vision contact lenses
Number of subjects: 294
Study 36169949 — intervention group
Group type: EXPERIMENTAL
Intervention: +2.50 D addition multifocal contact lenses
Number of subjects: 294
Study 33846036 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin therapy
Number of subjects: 2
Study 33846036 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic care and specific therapies (including intravenous aminophylline)
Number of subjects: 2
Study 33846036 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvalent immunoglobulins
Number of subjects: 2
Study 35865740 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% Kānuka oil cream
Number of subjects: 80
Study 35865740 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 80
Study 32965075 — intervention group
Group type: EXPERIMENTAL
Intervention: PEX168/100 μg
Number of subjects: 361
Study 32965075 — intervention group
Group type: EXPERIMENTAL
Intervention: PEX168/200 μg
Number of subjects: 361
Study 32965075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study 615917877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Ranibizumab (IVR)
Number of subjects: 44
Study 615917877 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR-PASCAL (Panphotocoagulation with PASCAL laser)
Number of subjects: 44
Study 615917877 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR-EDTRS (Panphotocoagulation with EDTRS laser)
Number of subjects: 44
Study 615917877 — intervention group
Group type: COMPARATOR
Intervention: Control (IVR alone)
Number of subjects: 44
Study 34281305 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-pocket delivery of Grape Seed Extract (GSE) with Scaling and Root Planing (SRP)
Number of subjects: 72
Study 34281305 — intervention group
Group type: COMPARATOR
Intervention: Scaling and Root Planing (SRP) alone
Number of subjects: 72
Study 32678914 — intervention group
Group type: EXPERIMENTAL
Intervention: MI varnish containing casein phosphopeptide‐amorphous calcium phosphate (CPP‐ACP) and 2.26% fluoride
Number of subjects: 2
Study 32678914 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat varnish containing 2.26% fluoride
Number of subjects: 2
Study 32678914 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish (no added calcium or fluoride)
Number of subjects: 2
Study 36057489 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox (80/20%)
Number of subjects: 53
Study 36057489 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 53
Study 36057489 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox responders (FEV1 improvement >10%)
Number of subjects: 53
Study 36057489 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox non-responders
Number of subjects: 53
Study 34812136 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month psychosocial intervention
Number of subjects: 402
Study 34812136 — intervention group
Group type: COMPARATOR
Intervention: brief psychoeducational intervention
Number of subjects: 402
Study 36382449 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic PEEK suture anchors (REJOIN Company)
Number of subjects: 55
Study 36382449 — intervention group
Group type: COMPARATOR
Intervention: Imported PEEK suture anchors (American Arthrex Company)
Number of subjects: 55
Study 35297777 — intervention group
Group type: EXPERIMENTAL
Intervention: MyCourse (digital, minimally guided smoking cessation intervention)
Number of subjects: 165
Study 35297777 — intervention group
Group type: COMPARATOR
Intervention: Control (noninteractive web-based information brochure)
Number of subjects: 165
Study 35297777 — intervention group
Group type: EXPERIMENTAL
Intervention: MyCourse
Number of subjects: 165
Study 35297777 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 165
Study 33606901 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop with faster-acting insulin aspart (Fiasp)
Number of subjects: 25
Study 33606901 — intervention group
Group type: COMPARATOR
Intervention: Hybrid closed-loop with standard insulin aspart
Number of subjects: 25
Study 35491363 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 325
Study 33265967 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mediterranean Diet Score (mMDS)
Number of subjects: 460
Study 36323602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual melatonin 3 mg
Number of subjects: 120
Study 36323602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 32894075 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive training targeting working memory updating (30 sessions over 6-8 weeks)
Number of subjects: 80
Study 32894075 — intervention group
Group type: COMPARATOR
Intervention: Low dose short-term memory program (placebo control)
Number of subjects: 80
Study 35714715 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous ulnar and radial artery compression (SURC), Group C
Number of subjects: 450
Study 35714715 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemostasis, Group A
Number of subjects: 450
Study 35714715 — intervention group
Group type: COMPARATOR
Intervention: Patent hemostasis, Group B
Number of subjects: 450
Study 32824483 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg AME
Number of subjects: 101
Study 32824483 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg AME
Number of subjects: 101
Study 32824483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 34151868 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-inflating bag (SIB)
Number of subjects: 20
Study 34151868 — intervention group
Group type: COMPARATOR
Intervention: T-piece (TP)
Number of subjects: 20
Study 34022425 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital literacy promotion (DLP) using e‐books
Number of subjects: 104
Study 34022425 — intervention group
Group type: COMPARATOR
Intervention: Standard literacy promotion (SLP) using board books
Number of subjects: 104
Study 32486622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IPE program)
Number of subjects: 116
Study 35749486 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen delivered by a face mask with reservoir
Number of subjects: 15
Study 35749486 — intervention group
Group type: COMPARATOR
Intervention: Room air delivered by a face mask with reservoir
Number of subjects: 15
Study 33797785 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 45
Study 33797785 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilisation Splint (SS)
Number of subjects: 45
Study 33797785 — intervention group
Group type: COMPARATOR
Intervention: Control Therapy (CT)
Number of subjects: 45
Study 33797785 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Frequency Parafunction (HFP)
Number of subjects: 45
Study 33797785 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Frequency Parafunction (LFP)
Number of subjects: 45
Study 32211767 — intervention group
Group type: COMPARATOR
Intervention: 0 mg Cr/d from Cr Prop
Number of subjects: 48
Study 32211767 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg Cr/d from Cr Prop
Number of subjects: 48
Study 32211767 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg Cr/d from Cr Prop
Number of subjects: 48
Study 32211767 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg Cr/d from Cr Prop
Number of subjects: 48
Study 32211767 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 or 4 mg Cr/d from Cr Prop
Number of subjects: 48
Study 34037752 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 0
Study 34037752 — intervention group
Group type: COMPARATOR
Intervention: Control (no testosterone treatment)
Number of subjects: 0
Study 35014110 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme E2 group (first-time pregnant women)
Number of subjects: 44
Study 35014110 — intervention group
Group type: COMPARATOR
Intervention: High E2 group (12 mg of E2 valerate)
Number of subjects: 44
Study 35014110 — intervention group
Group type: COMPARATOR
Intervention: Low E2 group (placebo)
Number of subjects: 44
Study 35014110 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme E2 group
Number of subjects: 44
Study 35915368 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility-based multidomain intervention (FMI)
Number of subjects: 152
Study 34085585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb761) at 200 μg/mL
Number of subjects: 0
Study 34085585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba intervention group
Number of subjects: 0
Study 34085585 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 0
Study 35597370 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid supplementation to rescue therapy
Number of subjects: 990
Study 32696210 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-etch (TE) technique with 37% phosphoric acid etching
Number of subjects: 35
Study 32696210 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch (SE) technique with no prior etching
Number of subjects: 35
Study 32886668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 98
Study 32886668 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 98
Study 34642949 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP0367 (bocidelpar sulfate) single doses of 1 to 120 mg
Number of subjects: 101
Study 34642949 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP0367 (bocidelpar sulfate) multiple once-daily doses of 10 to 75 mg
Number of subjects: 101
Study 34642949 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP0367 (bocidelpar sulfate)
Number of subjects: 101
Study 34642949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 35133996 — intervention group
Group type: EXPERIMENTAL
Intervention: ShoulderSphere (SS)
Number of subjects: 35
Study 35133996 — intervention group
Group type: EXPERIMENTAL
Intervention: TheraBand (TB)
Number of subjects: 35
Study 35133996 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 35
Study 36093695 — intervention group
Group type: EXPERIMENTAL
Intervention: Nichi Glucan 0.5g twice daily along with conventional treatment for 90 days
Number of subjects: 18
Study 36093695 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment comprising remedial behavioral therapies and L-carnosine 500 mg per day
Number of subjects: 18
Study 34435804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 134
Study 34435804 — intervention group
Group type: COMPARATOR
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 134
Study 34435804 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 134
Study 32732336 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous clearance of NG infection
Number of subjects: 720
Study 32732336 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to clearance
Number of subjects: 720
Study 32732336 — intervention group
Group type: COMPARATOR
Intervention: Chlamydia coinfection
Number of subjects: 720
Study 32732336 — intervention group
Group type: COMPARATOR
Intervention: Dysuria
Number of subjects: 720
Study 36381204 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-sacroiliac joint methylprednisolone injection (40 mg) plus NSAIDs and sulfasalazine (2 to 3 g/day)
Number of subjects: 60
Study 36381204 — intervention group
Group type: COMPARATOR
Intervention: Control group (no methylprednisolone injection)
Number of subjects: 60
Study 32108545 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic muscle tests (leg press)
Number of subjects: 15
Study 32108545 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic muscle tests (elbow flexion contralateral)
Number of subjects: 15
Study 32108545 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic muscle tests (elbow flexion affected arm)
Number of subjects: 15
Study 32108545 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic muscle tests (elbow extension)
Number of subjects: 15
Study 32108545 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic muscle tests (shoulder abduction contralateral)
Number of subjects: 15
Study 32108545 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic muscle tests (shoulder abduction affected arm)
Number of subjects: 15
Study 32108545 — intervention group
Group type: EXPERIMENTAL
Intervention: Test battery of dynamic muscle tests
Number of subjects: 15
Study 35801307 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual patient computer simulation
Number of subjects: 204
Study 35801307 — intervention group
Group type: EXPERIMENTAL
Intervention: Written simulation
Number of subjects: 204
Study 35801307 — intervention group
Group type: COMPARATOR
Intervention: No simulation control group
Number of subjects: 204
Study 34022938 — intervention group
Group type: EXPERIMENTAL
Intervention: PPM6: performance of two 30 min of cycling desk (using portable pedal exercise machine—PPM) per working day for 6 months
Number of subjects: 80
Study 34022938 — intervention group
Group type: COMPARATOR
Intervention: CTL_PPM3: 3 months with no intervention (control) followed by 3 months during which workers will be asked to complete two 30 min of PPM per working day
Number of subjects: 80
Study 32145825 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cisplatin 70 mg/m2 or carboplatin AUC4.5/AUC5 for GFR <50 mL/min, plus gemcitabine 1000 mg/m2 on days 1 and 8)
Number of subjects: 261
Study 32145825 — intervention group
Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 261
Study 36223044 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Connext intervention (integrates adversity screening and parent coaching)
Number of subjects: 27419
Study 36223044 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Connext intervention
Number of subjects: 27419
Study 36223044 — intervention group
Group type: COMPARATOR
Intervention: Control period
Number of subjects: 27419
Study 33892269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 500
Study 33892269 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 500
Study 33892269 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT) and Yoga
Number of subjects: 500
Study 33892269 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred treatment
Number of subjects: 500
Study 35244504 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO-OP) Approach
Number of subjects: 38
Study 35244504 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 38
Study 34197589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine D2/3 receptor antagonist amisulpride (400 mg)
Number of subjects: 44
Study 34197589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine D2/3 receptor agonist pramipexole (0.5 mg)
Number of subjects: 44
Study 34197589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 32075830 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone 20 mg per day for 5 days
Number of subjects: 398
Study 32075830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study 36088627 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional Vitamin D3
Number of subjects: 100
Study 36088627 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional MMR vaccine
Number of subjects: 100